Nonadherence to antiretroviral therapy among a community with endemic rates of injection drug use

Journal of the International Association of Physicians in AIDS Care

Volumn 4, Issue 3, 2005, Pages 66-72

  Shannon, Kate ^a   Kerr, Thomas ^a   Lai, Calvin ^a   Ishida, Tomiye ^a   Wood, Evan ^a,b   Montaner, Julio S G ^a,b   Hogg, Robert S ^a,b   Tyndall, Mark W ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

highly active antiretroviral therapy (HAART); injection drug use; nonadherence

Indexed keywords

HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; PATIENT COMPLIANCE; SUBSTANCE ABUSE; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL LOAD;

EID: 38149128055     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109705284353     Document Type: Article

References (37)

1. Porter K, Babiker A, Bhaskaran K, et al. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet. 2003 ; 362: 1267-1274. (Pubitemid 37324254)
2. Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ. 1999 ; 160: 659-665. (Pubitemid 29149796)
3. Wood E, Montaner JS, Tyndall MW, et al. Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy. J Infect Dis. 2003 ; 188: 1164-1170. (Pubitemid 37338981)
4. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999 ; 131: 81-87. (Pubitemid 29340558)
5. Montessori V, Press N, Harris M, Akagi L, Montaner JSG. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004 ; 170: 229-238. (Pubitemid 38134804)
6. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infections. J Acquir Immune Defic Syndr. 2001 ; 27: 251-259. (Pubitemid 32661966)
7. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002 ; 31 (suppl). S123 - S127.
8. Celentano DD, Vlahov D, Cohn S, et al. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998 ; 280: 544-546.
9. Bangsberg D, Tulsky JP, Hecht FM, et al. Protease inhibitors in the homeless. JAMA. 1997 ; 278: 63-65. (Pubitemid 27274519)
10. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998 ; 280: 547-549. (Pubitemid 28377675)
11. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000 ; 133: 21-30. (Pubitemid 30432540)
12. Press N, Tyndall MW, Wood E, et al. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2002 ; 31 (Suppl 3). S112 - S117.
13. Wood E, Schechter MT, Tyndall MW, et al. Antiretroviral medication use among injection drug users: two potential futures. AIDS. 2000 ; 14: 1229-1235. (Pubitemid 30420667)
14. Deeks SG. Determinants of virological response to antiretroviral therapy: implications for long-term strategies. Clin Infect Dis. 2000 ; 30 (Suppl 2). S177 - S184.
15. Bangsberg DR, Mundy LM, Tulsky JP. Expanding directly observed therapy: tuberculosis to human immunodeficiency virus. Am J Med. 2001 ; 110: 664-666. (Pubitemid 32510697)
16. Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997 ; 11: F59 - F65.
17. Wood E, Montaner JS, Yip B, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ. 2003 ; 169: 656-661. (Pubitemid 37266973)
18. Palepu A, Tyndall MW, Li K, et al. Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy. J Urban Health. 2003 ; 80: 667-675. (Pubitemid 38146230)
19. Palepu A, Tyndall MW, Li K, et al. Access and sustainability of antiretroviral therapy among injection drug users in Vancouver. Canadian Journal of Infectious Diseases. 2001 ; Supp B: 32B.
20. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998 ; 279: 450-454. (Pubitemid 28082255)
21. Kerr T, Palepu A, Barness G, et al. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver. Antivir Ther. 2004 ; 9: 407-414. (Pubitemid 38878756)
22. Yeni PG, Hammer S, Hirsch M, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004 ; 292: 251-265. (Pubitemid 38918003)
23. Hogg RS, Heath KV, Bangsberg D, et al. Intermittent use of triple combination therapy is predictive of mortality at baseline and after one year of follow-up. AIDS. 2002 ; 16: 1051-1058. (Pubitemid 34499429)
24. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001 ; 33: 1417-1423. (Pubitemid 32955198)
25. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000 ; 14: 357-366. (Pubitemid 30182431)
26. Bangsberg DR, Perry S, Charlebois ED, et al. Nonadherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001 ; 15: 1181-1183. (Pubitemid 32549871)
27. Stein MD, Rich JD, Maksad J, et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse. 2000 ; 26: 195-205. (Pubitemid 30366625)
28. Demas P, Schoenbaum E, Hirky AE, et al. The relationship of HIV treatment acceptance and adherence to psychological factors among injection drug users. AIDS and Behavior. 1998 ; 2: 283-292.
29. Carrieri MP, Moatti JP, Vlahov D, et al. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. J Epidemiol Community Health. 1999 ; 53: 4-8. (Pubitemid 29012343)
30. Antela A, Casado JL, Gonzalez MJ, et al. Influence of a methadone maintenance programme on the improved outcome of a cohort on injecting drug users with advanced HIV disease. AIDS. 1997 ; 11: 1405-1406. (Pubitemid 27423309)
31. Moreno A, Perez-Elias MJ, Casado JL, et al. Long-term outcomes of protease inhibitor-based therapy in antiretroviral treatment-naive HIV-infected injection drug users on methadone maintenance programmes. AIDS. 2001 ; 15: 1068-1070. (Pubitemid 32476680)
32. Sambamoorthi U, Warner LA, Crystal S, et al. Drug abuse, methadone treatment, and health services use among injection drug users with AIDS. Drug & Alcohol Dependence. 2000 ; 60: 77-89. (Pubitemid 30255988)
33. Moatti JP, Carrieri MP, Spire B, et al. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The MANIF 2000 Study Group. AIDS. 2000 ; 14: 151-155. (Pubitemid 30116440)
34. Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance abuse problems: the impact of substance abuse treatment. Addiction. 2004 ; 99: 361-368. (Pubitemid 38333828)
35. Roberts KJ. Physician-patient relationships, patient satisfaction, and antiretroviral medication adherence among HIV-infected adults attending a public health clinic. AIDS Patient Care STDS. 2002 ; 16: 43-50. (Pubitemid 34118922)
36. Murphy DA, Roberts KJ, Martin DJ, et al. Barriers to antiretroviral adherence among HIV-infected adults. AIDS Patient Care STDS. 2000 ; 14: 47-58. (Pubitemid 30056637)
37. De Irala J, Bigelow C, McCusker J, et al. Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population. Am J Epidemiol. 1996 ; 143: 725-732. (Pubitemid 26108239)